S-1: A new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer

Isamu Okamoto, Masahiro Fukuoka

Research output: Contribution to journalReview articlepeer-review

24 Citations (Scopus)

Abstract

S-1 (also known as TS-1; Taiho Pharmaceutical Co. Ltd.; Tokyo, Japan) is a new oral fluoropyrimidine formulation that combines tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate in a molar ratio of 1:0.4:1. Singleagent S-1 has demonstrated marked activity against non-small-cell lung cancer (NSCLC) as well as a broad array of other solid tumors, including gastric, colorectal, breast, cervical, and pancreatic cancers. This comprehensive review summarizes the results of previous clinical studies and describes ongoing clinical trials of S-1 in advanced NSCLC. S-1 combined with platinum compounds, irinotecan, and gemcitabine has produced promising results in terms of feasibility, safety, and effectiveness. Available data have stimulated further research, including phase III trials for the first-line treatment of advanced NSCLC.

Original languageEnglish
Pages (from-to)290-294
Number of pages5
JournalClinical Lung Cancer
Volume10
Issue number4
DOIs
Publication statusPublished - 2009
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'S-1: A new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this